Definium Therapeutics (NASDAQ:DFTX) Rating Increased to Strong-Buy at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Definium Therapeutics (NASDAQ:DFTX) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

DFTX has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Robert W. Baird lifted their price target on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Wall Street Zen upgraded shares of Definium Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Needham & Company LLC lifted their target price on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and an average target price of $52.36.

Definium Therapeutics Stock Performance

Shares of DFTX stock opened at $42.65 on Monday. The stock has a market capitalization of $4.25 billion, a price-to-earnings ratio of -17.13 and a beta of 2.20. Definium Therapeutics has a one year low of $7.96 and a one year high of $49.20. The company’s 50-day simple moving average is $34.09 and its 200-day simple moving average is $24.10. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities analysts anticipate that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other news, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 in the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DFTX. Royal Bank of Canada boosted its position in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares in the last quarter. Creative Planning raised its holdings in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the last quarter. Rhumbline Advisers lifted its stake in Definium Therapeutics by 6.3% during the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.